Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Drug Pricing Shake Up Likely In Germany

Top Pricing And Reimbursement Authority Wants To Slash Free Pricing Period

Executive Summary

The umbrella organization for public insurers is also expected to publish its own suggestions on how to cut spending on pharmaceuticals, including interim prices for conditionally approved drugs.

You may also be interested in...



EU Council Agrees Compromise Position On Joint Clinical Assessments

The Alliance For Regenerative Medicines is calling for advanced therapies to be given greater priority where joint clinical assessments are concerned.

Industry Welcomes Mandatory EU Joint Clinical Assessments For HTA

Draft proposals to improve EU-wide cooperation on health technology assessments, including mandatory joint clinical assessments, have won support from EFPIA, the European Federation of Pharmaceutical Industries and Associations.

Germany’s New Government Will Maintain Price Freeze And Slash Free Pricing Period

Big changes are in store on the drug pricing front in Germany. Further reforms could depend on who is appointed health minister.

Topics

UsernamePublicRestriction

Register

PS144336

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel